Nanoflex Robotics Receives Prestigious TOP 100 Swiss Startups Award

Nanoflex Robotics Ranks Top Among MedTech Startups in Switzerland

ZURICH, Switzerland, September 05, 2024 —Nanoflex Robotics announced today that it has received the TOP 100 Swiss Startup Award for the second consecutive year.

The company was ranked 10th on the TOP 100 Swiss Startup Ranking 2024 and was recognized as the top medical technology startup in Switzerland.

The award reflects Nanoflex Robotics’ progress in developing innovative telerobotic technologies aimed at revolutionizing endovascular interventions, particularly in the field of remote stroke treatments.

The TOP 100 Swiss Startup Award, organized by Venturelab, brings together the country’s top startups, evaluated by Swiss investors and industry experts. Each year, 100 of the most promising Swiss startups are picked by a panel of investors and startup experts. The jury then selects their favorite startups, each less than five years old, with the greatest commercial potential to join the ranking.

Ranking 10th among the most promising startups across all sectors reaffirms Nanoflex Robotics’ progress in developing groundbreaking innovation in the medical technology sector.

Matt Curran, Nanoflex Robotics CEO, received the award from Jordi Montserrat, Managing Partner at Venturelab.

“Being ranked once again in the TOP 100 Swiss Startups is an honor,” said Matt Curran, CEO of Nanoflex Robotics. “Our team has made remarkable progress in developing telerobotic systems that aim to transform how critical interventions like stroke treatments are performed and we are grateful for this recognition.”

 

About Nanoflex Robotics AG

Nanoflex Robotics is building a next-generation telerobotics interventional platform to enhance access to life-saving procedures. The first target application of the Remote Intervention System (RIS) is to enable telerobotic mechanical thrombectomies in acute ischemic stroke patients where timely intervention is critical. Our system combines unique advanced magnetic navigation technology and ultra-flexible endoluminal robotic tools to give physicians greater control and dexterity over procedures, allowing for safer and more precise interventions.

To learn more, please visit: www.nanoflexrobotics.com

Back to top

Nanoflex Robotics has been chosen as one of the 25 winners of the prestigious Falling Walls Venture global competition.

The Falling Walls Science Summit, held annually in November in Berlin, is a leading international forum that celebrates groundbreaking scientific achievements across disciplines and sectors.

This year, the 25 winning science startups represent 36 countries and span various industries, including medical technology, biotechnology, clean technology, and quantum technologies.

Together with these innovative startups, Nanoflex Robotics will present our technology at the Summit, to compete for the coveted title of “Science Breakthrough of the Year.”

Read more here.

 

 

Back to top

Nanoflex Robotics, a Swiss medtech startup, has appointed the former CEO of CMR Surgical to its Board.

ZURICH, Switzerland, August 05, 2024 — Nanoflex Robotics is pleased to announce that it has appointed Per Vegard Nerseth, the former Chief Executive Officer of CMR Surgical, as an independent Non-Executive Director effective immediately.

Per Vegard brings over three decades of global business experience, including developing high-performing teams and launching new ventures in the robotics sector. Most recently, Per Vegard was the CEO of CMR Surgical, where he also served on the Board. Prior to CMR Surgical, Per Vegard held multiple portfolios at ABB, where he steered business lines’ turnarounds and optimized for long-term strategic growth.

Per Vegard’s track record of navigating complex markets and scaling cutting-edge technologies makes him a crucial addition to Nanoflex Robotics’s Board. His expertise is especially valuable as the company looks to accelerate the development of its innovative telerobotics system to treat acute ischemic stroke and bring it to market.

“We are thrilled to welcome Per Vegard to our Board. His extensive leadership experience and deep understanding of complex regulatory markets will be invaluable to Nanoflex Robotics as we aim to complete our first-in-human procedures next year and commence clinical studies thereafter,” said Matt Curran, CEO of Nanoflex Robotics.

“I am honored to join the Board of Nanoflex Robotics. I admire the company’s big vision in developing a telerobotic platform to treat acute ischemic stroke. I look forward to contributing to the company’s future success and working with such a talented and dedicated team,” said Per Vegard Nerseth.

Nanoflex Robotics is a Swiss medical device startup that aims to enhance accessibility to life-saving interventions through telerobotics. The first application of the company’s Remote Intervention System (RIS) is to enable a remote thrombectomy for patients suffering from acute ischemic stroke. The RIS is currently undergoing final product refinement and pre-clinical testing with the aim of conducting its first-in-human procedure in 2025.

About Nanoflex Robotics AG

Nanoflex Robotics is building a next-generation telerobotics interventional platform to enhance access to life-saving procedures. The first target application of the Remote Intervention System (RIS) is to enable telerobotic mechanical thrombectomies in acute ischemic stroke patients where timely intervention is critical. The RIS combines unique advanced magnetic navigation technology and ultra-flexible endoluminal robotic tools to give physicians greater control and dexterity over procedures, allowing for safer and more precise interventions that enhance patient care, reduce complications, and improve overall outcomes. To learn more, please visit: www.nanoflexrobotics.com

Back to top

The innovative medical robotic startup achieved the globally recognized ISO 13485 certification in December 2023

ZURICH, Switzerland, Jan. 10, 2024 (GLOBE NEWSWIRE) — Nanoflex Robotics AG, a remote robotic surgical company based in Switzerland, has received the internationally recognized ISO 13485 certification for its quality management system in designing and manufacturing remote robotic devices for endovascular interventions.

The ISO 13485 certification is the global standard for quality management systems within the medical device industry. To become certified, companies must demonstrate that important components are designed and manufactured in accordance with stringent regulatory standards.

The certification represents Nanoflex Robotics’ commitment to upholding high standards throughout its entire operational chain, from the initial phases of research and development to design and manufacturing. It is a step forward in bringing to market innovative remote robotic solutions that are designed to increase access to critical care procedures, such as the treatment of acute ischemic stroke.

“We are thrilled to receive the ISO 13485 certification for our quality management system. It is an important milestone in our journey to revolutionize stroke care and reflects our desire to deliver innovative, safe, and high-quality robotic solutions that make a real difference in patient outcomes,” said Matt Curran, CEO of Nanoflex Robotics.

Nanoflex Robotics’ first product will be a compact remote robotics system that utilizes a control unit and magnetism to guide ultra-flexible devices through the body for a range of complex interventions. The company aims to make remote mechanical thrombectomies a reality through remote robotics surgery, thereby shortening the time to treatment and preserving the quality of life for stroke patients.

About Nanoflex Robotics AG

Nanoflex Robotics is building next-generation remote robotic surgical solutions and devices to enhance access to life-saving procedures. The Nanoflex Robotics platform’s first target application is to enable remote mechanical thrombectomies in acute ischemic stroke patients where timely intervention is critical.

Nanoflex Robotics’ unique advanced magnetic navigation technology and ultra-flexible endoluminal robotic tools aims to give physicians greater control and dexterity over procedures, allowing for safer and more precise interventions that enhance patient care, reduce complications, and improve overall outcomes.

Additionally, the platform is being developed to facilitate various other procedures that can be executed comfortably and conveniently by in-person physicians. The platform’s compact and mobile design enables seamless integration into diverse clinical settings and operating rooms, underscoring its versatility as a robotic assistant tailored for hospital environments.

For media inquiries please contact:

ir@nanoflexrobotics.com

Back to top

The funding will drive first-in-human and regulatory clearance of the company’s robotic platform to precisely steer wires and catheters through vasculature using electromagnetic fields.

Zurich, Switzerland, February 2023 - Nanoflex Robotics AG, a pioneer in magnetically controlled medical soft robotics, today announced that it has achieved an initial $12 million in funding. Nanoflex Robotics will use the funding to bring its first-generation system to market and to accelerate development of new neurointerventional products A first-in-human trial and FDA submission is planned for Q3 2023. 

The financing round is led by Ascend Capital Partners, an international venture capital firm focused on investments in MedTech and Mobility early-stage tech companies. The financing round is supported by European based family offices, including Kinled Holding Ltd, an experienced medical device/robotics investor with a significant track record of identifying successful spin outs from EPFL/ETH Zurich, and Mountain Labs AG, an incubator specialized in funding innovative technology.  

Nanoflex Robotics aims to revolutionize catheter-based treatment of neurovascular and vascular disease by enabling faster and safer access to target sites in the vasculature. Our robotic system allows precise and flexible steering of magnetically-adapted guide wires and catheters, while potentially decreasing X-ray exposure for the physician,” said Matt Curran, CEO of Nanoflex Robotics AG. “We are excited to partner with Ascend Capital Partners, Kinled and Mountain Labs to make our goal of safe remote treatment for acute ischemic stroke a reality.”Nanoflex Robotics was founded in Zurich in 2021 by Prof. Bradley Nelson, Dr. Christophe Chautems and Matt Curran. Its proprietary technology to generate and control electromagnetic fields for endovascular navigation of magnetic devices is based on over 20 years of research at ETH Zurich, the Swiss Federal Institute of Technology. The project continues to receive support from ETH Zurich and Wyss Zurich. 

Jerry Hong, CEO of Ascend Capital Partners, who will join the board of directors, commented: “We are excited to support this exceptional team in reinventing the surgical robotic space with remote vascular interventions. We especially recognize its potential to achieve more equitable patient access to timely mechanical thrombectomies, which are very effective for preserving the post-stroke quality of life for patients. 

Nanoflex Robotics’ first product will be a compact and mobile electromagnetic field generator that can easily be moved between hospital interventional suites, requiring no additional infrastructure beyond a high voltage electrical point and access to a water-based cooling system. The system allows direct tip control of magnetically adapted interventional devices, in contrast to conventional procedures where torque must often be transferred more than a meter down the length of devices to control tip direction.  

About Nanoflex Robotics 

Nanoflex Robotics, a Zurich (Switzerland) based MedTech start-up, has developed a proprietary robotic platform to navigate magnetic devices in complex vascular anatomy using precise electromagnetic fields. Its portfolio of products is intended to diagnose and treat vascular disease, including acute ischemic stroke, in a timely and safe manner. For more information, please visit Nanoflex Robotics. 

Investors & supporters 

Ascend Capital Partners is a leading international venture capital and financial advisory firm committed to working with innovative companies who have potential to grow and expand internationally, particularly in Europe, Asia, and the United States. With extensive regional and international networks and insight into Chinese and Western capital market worlds, Ascend has set itself apart from other pure advisory firms and pure private equity funds. For more information, please visit Ascend Capital Partners. 

Kinled Holding is a partner in four dedicated life science investment companies based in Boston, Vienna, Gibraltar and Zurich, with combined Assets Under Management of $250M. Kinled Holding and the Aisher Family have long believed in fostering academic projects to become commercial businesses. The company has exited 19 investments via IPO and a further dozen through trade sales to strategics such as Astra-Zeneca, Medtronic, Globus and J&J. For more information, please visit Kinled. 

Mountain Labs is an incubator that focuses on earlystage technology investments in Switzerland and Austria. They assist other like-minded family offices and investment companies to better understand the risks and opportunities of investing in earlystage tech and FinTech and have developed a strong network of relationships with national universities and technology transfer offices. For more information, please visit Mountain Labs. 

The Wyss Zurich Translational Center (Wyss Zurich) is a joint accelerator of the University of Zurich and ETH Zurich (Swiss Federal Institute of Technology Zurich), which was made possible by a generous donation from the Swiss entrepreneur and philanthropist Dr. h.c. mult. Hansjörg Wyss. It was established to foster translational research focused on developing treatment protocols and clinical therapies, as well as novel technologies and intelligent systems, in the emerging fields of regenerative medicine robotics, and hybrid technologies thereof. Wyss Zurich unites world-leading experts from both institutions in multidisciplinary teams, pooling their knowledge and expertise. For more information, please visit Wyss Zurich. 

Back to top